[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42

Advertisement
4. Weinreb I, Perez-Ordoñez B: Non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. Report of 2 cases and review of the literature. Head Neck Pathol; 2007 Sep;1(1):21-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. Report of 2 cases and review of the literature.
  • Non-small cell neuroendocrine carcinomas (NSNECs) of the sinonasal tract are rare.
  • The first had a tumor involving left ethmoid sinus and nasal cavity and the second, a neoplasm involving nasopharynx, sphenoid sinus, with bilateral involvement of cavernous sinuses.
  • The second is alive with locally advanced disease 7 years after radiotherapy and chemotherapy.
  • Other cases do not show specific features and are probably best regarded as "neuroendocrine carcinoma, NOS".
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Nasal Cavity / pathology. Nasopharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Jul;27(1):79-82 [7557912.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):826-32 [9712424.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e3 [16119901.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):562-9 [6091074.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1617-22 [11037813.001]
  • [Cites] Rhinology. 2001 Mar;39(1):52-4 [11340699.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):330-9 [6243246.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2388-405 [7139532.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • (PMID = 20614276.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807510
  • [Keywords] NOTNLM ; Carcinoid tumor / Nasal cavity / Neuroendocrine carcinoma / Olfactory neuroblastoma / Paranasal sinuses / Small cell carcinoma
  •  go-up   go-down


5. Zagolski O, Dwivedi RC, Subramanian S, Kazi R: Non-Hodgkin's lymphoma of the sino-nasal tract in children. J Cancer Res Ther; 2010 Jan-Mar;6(1):5-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma of the sino-nasal tract in children.
  • Of all head and neck cancers occurring in children, non-Hodgkin's lymphoma (NHL) is the most common, others being rhabdomyosarcoma and nasopharyngeal carcinoma.
  • These can be of several different types depending on the predominant cell type and histologic appearance, the most common histological variant being diffuse large B-cell lymphoma.
  • In an attempt to simplify the classification and to develop a universally acceptable classification and staging, they have been classified and staged numerous times over the last three decades, adding more confusion to the topic.
  • Clinical presentations vary according to the histological type.
  • The low grade lymphomas present with a nasal cavity or para-nasal sinus mass associated with obstructive symptoms and/or lymphadenopathy, while high grade lymphomas present with aggressive signs and symptoms including non-healing ulcer, epistaxis, septal perforation and bony destruction.
  • The primary treatment consists of chemotherapy and / or radiation therapy, which is able to achieve remission in two-third of the patients, however, prognosis remains poor with cumulative five-year survival rates at about 30% for all the types of sino-nasal NHLs.
  • Newer targeted therapy (monoclonal antibodies) and combination therapies (including stem cells) are currently being tested in order to improve survival rates in these patients.
  • This article aims at providing an overview of clinico-epidemiologic characteristics, staging system currently in use, management, prognosis and possibilities of future research in the field of childhood sinonasal NHLs.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Nose Neoplasms / pathology. Paranasal Sinus Diseases / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Neoplasm Staging. Prognosis. Radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479539.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


6. Chamberlain MC: Treatment of intracranial metastatic esthesioneuroblastoma. Cancer; 2002 Jul 15;95(2):243-8
Genetic Alliance. consumer health - Esthesioneuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of intracranial metastatic esthesioneuroblastoma.
  • To the authors' knowledge there is no current consensus regarding treatment.
  • The current study was conducted to determine the toxicity and response rate of combined modality therapy in the treatment of patients with ENB metastatic to the brain.
  • CNS-directed therapy included radiotherapy (to the brain in three patients and to the spine in two patients) and chemotherapy (systemic in six patients and regional in three patients).
  • Systemic chemotherapy was comprised of carboplatin, lomustine, and vincristine administered every 2 months.
  • RESULTS: Between 1-6 cycles of systemic chemotherapy were administered (median, 4.5 cycles).
  • and 6-19 cycles of regional chemotherapy were administered (median, 17 cycles).
  • Toxicity included aseptic meningitis (three patients), radiation enteritis (one patient), and > or = Grade 3 (according to the National Cancer Institute Common toxicity Criteria) myelosuppression (four patients).
  • No treatment-related deaths were reported.
  • CONCLUSIONS: In the small cohort of patients in the current study, combined modality therapy was found to have modest toxicity and palliative efficacy.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Central Nervous System Neoplasms / therapy. Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Ethmoid Sinus. Female. Humans. Male. Middle Aged. Nasal Cavity. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10679
  • (PMID = 12124822.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sites were nasopharynx-nasal cavity, middle ear/mastoid and parapharyngeal area ("better" sites, 55%), paranasal sinus and infratemporal-pterygopalatine area ("worse" sites, 42%), and other (3%).
  • Treatment included vincristine, actinomycin D, and cyclophosphamide (VAC) chemotherapy and radiotherapy to the primary tumor and up to five metastatic sites/tissues.
  • Sixty patients had progressive disease (N = 49) or death as a first event (N = 11); another developed myelodysplastic syndrome and died.
  • Patients with the best outlook had embryonal RMS located in the nasopharynx/nasal cavity, middle ear/mastoid, or parapharyngeal region.
  • Distant metastases were the most frequent type of recurrence, indicating that more effective systemic agents are needed to eliminate residual disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


8. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V, Garcia J, Lee NY, Kaplan MJ, El-Sayed I, Eisele DW, Fu KK, Phillips TL: Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):141-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement?
  • PURPOSE: To compare clinical outcomes of patients with carcinomas of the paranasal sinuses and nasal cavity according to decade of radiation treatment.
  • METHODS AND MATERIALS: Between 1960 and 2005, 127 patients with sinonasal carcinoma underwent radiotherapy with planning and delivery techniques available at the time of treatment.
  • Nineteen patients (15%) received chemotherapy.
  • The most common histology was squamous cell carcinoma (83 patients).
  • There were no significant differences in any of these endpoints with respect to decade of treatment or radiotherapy technique (p > 0.05, for all).
  • CONCLUSION: Although we did not detect improvements in disease control or overall survival for patients treated over time, the incidence of complications has significantly declined, thereby resulting in an improved therapeutic ratio for patients with carcinomas of the paranasal sinuses and nasal cavity.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiation Injuries / prevention & control. Radiotherapy / adverse effects. Radiotherapy / trends. Radiotherapy, Conformal / adverse effects. Radiotherapy, Intensity-Modulated / adverse effects. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459609.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Day TA, Beas RA, Schlosser RJ, Woodworth BA, Barredo J, Sharma AK, Gillespie MB: Management of paranasal sinus malignancy. Curr Treat Options Oncol; 2005 Jan;6(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of paranasal sinus malignancy.
  • Malignancies of the nasal cavity and paranasal sinuses represent a wide spectrum of histologies, tissues of origin, and anatomic primary sites.
  • The inherent difficulty in generalizing treatment approaches is obvious, given the numerous variables associated with the broadly-based term, paranasal sinus malignancy (PNSCa).
  • Nevertheless, the majority of epithelial and salivary malignancies of this region (ie, squamous cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, sinonasal undifferentiated carcinoma, and esthesioneuroblastoma) require surgical intervention as part of any treatment regimen.
  • Nonepithelial malignancies, including the wide variety of sarcomas arising in this region, most commonly require multimodality treatment including chemotherapy, radiation, and/or surgery for definitive treatment.
  • Moreover, the proximity of the nasal cavity and paranasal sinuses to structures including the orbit, dura, brain, cranial nerves, and carotid arteries mandates careful radiologic and neurologic evaluations throughout the course of the disease.
  • However, additional clinical trials are necessary to systematically evaluate the locoregional control, organ-preservation strategies, and survival related to the variety of treatments currently available.
  • [MeSH-major] Carcinoma / surgery. Melanoma / surgery. Paranasal Sinus Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diet. Humans. Life Style. Prognosis. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Head Neck. 1995 Jul-Aug;17(4):303-11 [7672971.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Med Pediatr Oncol. 1999 Oct;33(4):362-71 [10491544.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):335-41 [14716769.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):219-23 [10439167.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck Surg. 1980 May-Jun;2(5):410-9 [7364592.001]
  • [Cites] Am J Otolaryngol. 2004 May-Jun;25(3):162-6 [15124164.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1157-62 [11583200.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):450-9 [12110339.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Laryngoscope. 2002 Oct;112(10):1871-6 [12368633.001]
  • [Cites] Oncology (Williston Park). 2000 Nov;14(11A):163-94 [11195409.001]
  • [Cites] Otolaryngol Clin North Am. 1995 Dec;28(6):1239-57 [8927395.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Jul;129(1):77-84 [12869921.001]
  • [Cites] Otolaryngol Clin North Am. 2004 Apr;37(2):473-87 [15064075.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Am J Rhinol. 2002 Jul-Aug;16(4):221-7 [12222948.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):158-68 [12694834.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Am J Rhinol. 2002 Sep-Oct;16(5):281-6 [12422974.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):84-9 [15305080.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Oncology (Williston Park). 1992 Jan;6(1):43-50; discussion 55-6 [1531603.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):361-9 [9607352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9 [9308929.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):594-611 [12717245.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):290-4 [11452937.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7 [12165452.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):233-40 [12707712.001]
  • [Cites] Head Neck. 2004 Feb;26(2):136-44 [14762882.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):197-201 [11936913.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):204-13 [10623711.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):743-6 [8318204.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):147-54 [14697432.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):9-15 [15100926.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1996;50(1):19-24 [8669267.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Am J Surg Pathol. 1986 Mar;10 (3):192-202 [3953940.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5108-12 [8221646.001]
  • [Cites] Head Neck. 2004 May;26(5):435-41 [15122660.001]
  • [Cites] Head Neck. 2003 Oct;25(10):791-8 [12966502.001]
  • [Cites] Head Neck Surg. 1980 Jul-Aug;2(6):497-508 [6248488.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2000;54(2):221-32 [10892511.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Jan;3(1):17-21 [1705815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):823-9 [9369129.001]
  • [Cites] Epidemiology. 1998 Sep;9(5):518-24 [9730030.001]
  • [Cites] Eur J Nucl Med. 2001 Jul;28(7):816-21 [24770459.001]
  • [Cites] J Laryngol Otol. 1992 Dec;106(12):1063-6 [1487661.001]
  • [Cites] J Neurosurg. 1995 Jun;82(6):1002-10 [7760173.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1450-5 [12172261.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):208-10 [10439164.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):574-7 [7822181.001]
  • [Cites] Hum Pathol. 2003 Nov;34(11):1101-7 [14652810.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Mar;129(3):334-7 [12622544.001]
  • [Cites] Cancer. 1999 Nov 1;86(9):1700-11 [10547542.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):255-64 [10421261.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3743-9 [11268448.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Head Neck. 2004 Jul;26(7):584-93 [15229900.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):167-86 [15062368.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):147-57 [11936821.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] Otolaryngol Head Neck Surg. 1999 Mar;120(3):387-90 [10064643.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):776-84 [12573765.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):193-200 [1924855.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):932-7 [15333652.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):105-12 [12704690.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1241-57, xi [11728944.001]
  • [Cites] Am J Epidemiol. 1994 Aug 15;140(4):340-9 [8059769.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1597-604 [12459626.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):101-7 [10361593.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Feb;47(1):1-8 [15100925.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Oct;46(5):310-5 [14628249.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):318-31 [11567805.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15610711.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


10. Daele JJ, Vander Poorten V, Rombaux P, Hamoir M: Cancer of the nasal vestibule, nasal cavity and paranasal sinuses. B-ENT; 2005;Suppl 1:87-94; quiz 95-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the nasal vestibule, nasal cavity and paranasal sinuses.
  • The usual clinical presentation of sinonasal tumours includes symptoms that are indistinguishable from inflammatory sinus disease, namely nasal airway obstruction, pain, and epistaxis.
  • Computed tomography is the most reliable and informative imaging tool for evaluating the cancers of the paranasal sinuses.
  • Magnetic resonance imaging is essential for tumour mapping because of the excellent tissue characterisation and the possibility of differentiating between neoplasms and retained secretions.
  • A wide variety of histologies may be encountered, although squamous cell carcinoma (SCCA) is the most common.
  • The response of sinonasal tract tumours to radiation therapy varies with the stage and histology of the tumour.
  • Management of these tumours requires a multimodal approach, involving surgery, radiation therapy and, increasingly in recent years, chemotherapy.
  • [MeSH-major] Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363270.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 49
  •  go-up   go-down


11. Bień S, Kobiorska-Nowak J: [Plasmocytoma in the nasal cavity and paranasal sinuses]. Otolaryngol Pol; 2009 May-Jun;63(3):287-92
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Plasmocytoma in the nasal cavity and paranasal sinuses].
  • The most common localization of extramedullary plasmocytoma is a mucosa of the nasal cavity and paranasal sinuses.
  • MATERIAL: Case reports of three cases of plasma cell myeloma localised within the nose and paranasal sinuses; diagnosed and treated in Holy Cross Cancer Center- Kielce, Poland, from 2001 to 2008.
  • CASES PRESENTATION: Case I-- Male 49 years old--Extramedullary plasmocytoma localized in mucosa of the floor of nasal cavity.
  • Treated with radical Rtg-therapy.
  • Case II--Male 42 years old--Multiple myeloma with one of focuses in anterior wall of maxillary sinus.
  • Treated with radical Rtg-therapy and Chemotherapy.
  • Case III--Male 29 years old--Multiple myeloma with one of the focuses in posterior wall of maxillary sinus.
  • Treated with radical Rtg-therapy and Chemotherapy.
  • (1) Plasma cell myelomas in the nose and paranasal sinuses region are a rare tumors.
  • They may manifest as an isolated form of plasmocytoma, or a generalized disease as a one of focuses in the bone frame of the nose and sinuses or one of the focuses outside the bone. (2) The complex diagnosis and treatment of plasma cell myelomas require a multispecialistic approach, and should be conducted in oncological centers. (3) The ceases presented confirm, that a generalized myelomas usually have a bad prognosis.
  • [MeSH-major] Multiple Myeloma / radiotherapy. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy. Plasmacytoma / therapy
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Middle Aged. Nasal Cavity / pathology. Nasal Mucosa / pathology. Paranasal Sinuses / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886539.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


12. Porceddu S, Martin J, Shanker G, Weih L, Russell C, Rischin D, Corry J, Peters L: Paranasal sinus tumors: Peter MacCallum Cancer Institute experience. Head Neck; 2004 Apr;26(4):322-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paranasal sinus tumors: Peter MacCallum Cancer Institute experience.
  • BACKGROUND: The purpose of this study was to evaluate the local control, pattern of recurrence, overall survival, and prognostic factors of patients with squamous cell carcinoma (SCC), adenocarcinoma, and undifferentiated carcinoma of the paranasal sinuses (PNS) and nasal cavity (NC) presenting to our center for curative treatment over a 10-year period.
  • METHODS: Between 1991 and 2000, 60 patients with SCC (n = 32), adenocarcinoma (n = 25), and undifferentiated carcinoma (n = 3) of the PNS or NC were identified.
  • Forty patients received surgery and postoperative radiotherapy, four surgery alone; 11, radiotherapy alone; three radical radiotherapy after surgical recurrence; one, chemoradiotherapy and surgery; and one, induction chemotherapy followed by radiotherapy.
  • [MeSH-major] Carcinoma / mortality. Nasal Cavity / pathology. Nose Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia / epidemiology. Blindness / etiology. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Nervous System Neoplasms / secondary. Orbital Neoplasms / secondary. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15054735.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Samson JF, Suja V, Samad AK, George AE, Sankar S: Sinonasal carcinoma masquerading as fungal sinusitis. Indian J Dermatol Venereol Leprol; 2006 Nov-Dec;72(6):470
MedlinePlus Health Information. consumer health - Sinusitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal carcinoma masquerading as fungal sinusitis.
  • Later a skin biopsy from the indurated lesion showed moderately differentiated squamous cell carcinoma.
  • A diagnosis of sinonasal carcinoma was made and chemotherapy was started.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Mycoses. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Sinusitis / diagnosis. Sinusitis / microbiology

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17186638.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


14. Hameed S, Jamshed A, Hussain R, Ali M, Iqbal H, Majeed U, Shah MA: Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors. J Clin Oncol; 2009 May 20;27(15_suppl):6055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors.
  • : 6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial.
  • The disease is chemosensitive and there is increasing interest in the use of chemotherapy with radiation in this group of patients.
  • Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT).
  • METHODS: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution.
  • Site of disease was nasal cavity 33% (7), ethamoid sinus 43% (9), maxillary antrum 19% (4), and frontal sinus in 5% (1) of patients.
  • Histopathological diagnosis was squamous cell carcinoma 43% (9), undifferentiated carcinoma 29% (6), adenocarcinoma 19% (4), esthesioneuroblastoma in 9% (2) of patients.
  • Induction chemotherapy consisted of cisplatin 75 mg / metre<sup>2</sup> day 1 and gemcitabine 1 gm / metre<sup>2</sup> day 1 and 8 every three weeks.
  • Eighty-five percent (18/21) received 2 cycles of neoadjuvant chemotherapy (range 1-4 cycles) prior to radiotherapy.
  • Radiotherapy dose was 54 Gy - 70 Gy (median radiation dose 66 Gy).
  • RESULTS: Response to neoadjuvant chemotherapy; complete in 19% (4), partial in 67% (14), no response/progression 14% (3).
  • Thirty-three percent (7/21) have failed treatment (local 3, regional 2, and distant metastasis in 2 patients).
  • Among treatment failures 2 patients were successfully salvaged; surgery for local recurrence in one patient and in the other case radiation was given for regional recurrence.
  • CONCLUSIONS: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Diba R, Saadati HG, Esmaeli B: Outcomes of dacrocystorhinostomy in patients with head and neck tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):5584

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Cancer Center between 1999 and 2003 were retrospectively reviewed for outcome and complications of DCR.
  • The tumor diagnoses were as follows: squamous cell carcinoma (SCCA), 18 patients (16 had paranasal-sinus SCCA and 2 had skin SCCA); chondrosarcoma, 3; sinonasal carcinoma, 2; adenoid cystic carcinoma, 2; sinonasal papilloma, 2; esthesioneuroblastoma, 1; hemangiopericytoma,1; ameloblastoma,1; and ostoesarcoma,1.
  • Twenty-one patients had a maxillectomy and 7 patients had other sinus surgeries before DCR.
  • Six patients had had silicone intubation at the time of maxillectomy but later developed epiphora and nasolacrimal duct blockage.
  • Ten patients had radiotherapy and 14 had chemotherapy and radiotherapy before DCR.
  • The mean time between completion of radiotherapy and DCR was 24 months (median, 31.5 months), and the mean time between completion of chemotherapy and DCR was 21.5 months (median, 12.5 months).
  • In 1 of these 4 patients, tumor recurrence in the nasal cavity was the cause; he subsequently underwent a total rhinectomy.
  • None of the patients who had had radiotherapy developed osteoradionecrosis.
  • Two patients had mild wound infections, which resolved after 1 week of systemic antibiotic therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Wiseman SM, Popat SR, Rigual NR, Hicks WL Jr, Orner JB, Wein RO, McGary CT, Loree TR: Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J; 2002 Aug;81(8):510-4, 516-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases.
  • We retrospectively reviewed 35 cases of adenoid cystic carcinoma that had originated in the minor salivary glands of the paranasal sinuses or nasal cavity.
  • Twenty patients had been treated with surgery and adjuvant radiotherapy, 10 patients with surgery alone, three with radiotherapy alone, and two with concurrent radiotherapy and chemotherapy.
  • During the study, 22 patients developed recurrent disease--11 locally; three distantly; seven locally and distantly; and one locally, regionally, and distantly.
  • Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity is an aggressive neoplasm that results in a high incidence of both local recurrence and distant metastasis, regardless of treatment modality.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / epidemiology. Nose Neoplasms / diagnosis. Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12199167.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


17. Jurkiewicz D, Wojdas A, Hermanowski M: [Malignant tumors of the nose and paranasal sinuses in the years 1971-2005 in the material of the Otolaryngology Clinic WIM]. Otolaryngol Pol; 2007;61(4):572-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the nose and paranasal sinuses in the years 1971-2005 in the material of the Otolaryngology Clinic WIM].
  • The aim of this study was retrospective analysis of evidence concerning to malignant tumors of the nasal cavity and the paranasal sinuses diagnosed in Otolaryngology Clinic of the Military Institute of the Health Service 1971-2005.
  • The methods of therapy were also discussed.
  • MATERIAL AND METHODS: Material comprised 113 patients (35 females and 78 males) with diagnosis of malignant tumors of the nose and paranasal sinuses.
  • The clinical aspects, sex, age, TNM classification and therapy methods (surgery, radiotherapy, chemotherapy) were analysed.
  • Three of patients did not agree for therapy.
  • CONCLUSIONS: The most frequent of malignant tumors of the nose and paranasal sinuses was cancer.
  • The method of choice in treatment is surgery combined with postoperative radiation.
  • [MeSH-major] Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260254.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


18. Airoldi M, Garzaro M, Valente G, Mamo C, Bena A, Giordano C, Pecorari G, Gabriele P, Gabriele AM, Beatrice F: Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology; 2009;76(4):262-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region.
  • OBJECTIVES: In spite of aggressive surgery and high-dose radiotherapy, the long-term survival of patients with sinonasal cancer remains disappointing.
  • Patients treated with surgery with or without radiotherapy had better survival (p < 0.01), while chemotherapy had a marginally favorable effect (p = 0.09).
  • The type of surgery and radiotherapy dose had no impact on survival; in contrast, there was a strong association between Ki-67 expression and microvessel density and overall survival (p < 0.05 and p = 0.039, respectively), while VEGF-C was a prognostic factor in SCC patients only (p < 0.05).
  • CONCLUSIONS: In sinonasal cancer, tumor stage and histology have a clear impact on survival; surgery with or without radiotherapy represents the main choice of treatment for such tumors.
  • The proliferative index and angiogenesis show a major role in the natural history of this cancer.
  • [MeSH-major] Paranasal Sinus Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD31 / analysis. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vascular Endothelial Growth Factor C / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19258726.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


19. Kin S, Wanibuchi M, Minamida Y, Yamaki T, Tanabe S, Houkin K: [A case of sinonasal carcinoma with intracranial invasion treated by a multidisciplinary team]. No Shinkei Geka; 2003 Jun;31(6):677-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sinonasal carcinoma with intracranial invasion treated by a multidisciplinary team].
  • We report a case of a 66-year-old male with diffuse infiltration of neoplasm from the paranasal sinuses to the orbit and left cerebral hemisphere, associated with prominent edema.
  • Neuroimaging showed marked invasion of a neoplasm from the left paranasal sinuses into the intracranial space and to the frontal skull.
  • The pathological diagnosis was "poorly differentiated carcinoma from the paranasal sinus".
  • Postoperatively the patient received radiation and chemotherapy.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Small Cell / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male. Neoplasm Invasiveness. Skull Base Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12833878.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Ng W, Jacob S, Delaney G, Barton M: Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care. Eur J Cancer; 2009 Aug;45(12):2150-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
  • BACKGROUND: We estimated the optimal chemotherapy utilisation rate for head and neck cancer as a benchmark for measuring and improving the quality of cancer care.
  • METHODS: An optimal chemotherapy utilisation tree was constructed using indications for chemotherapy that were identified from evidence-based treatment guidelines.
  • Data on the proportion of patient and tumour-related attributes for which chemotherapy was indicated were obtained and merged with the treatment indications to calculate the optimal utilisation rate.
  • The optimal chemotherapy utilisation rate was compared with actual utilisation rates reported.
  • RESULTS: Chemotherapy is indicated at least once in 36% (95% CI, 33-38%) of all patients with head and neck carcinoma.
  • The optimal utilisation rates by subsites were as follows: lip, 8%; oral cavity, 40%; nasopharynx, 69%; oropharynx, 66%; hypopharynx, 74%; larynx, 43%; salivary gland, 48% and paranasal sinus with nasal cavity, 38%.
  • CONCLUSIONS: The optimal proportion of patients who should receive chemotherapy in the head and neck carcinoma population has risen significantly over the past 20 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285857.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Wei-wei L, Qiu-liang W, Guo-hao W, Zhi-hua C, Zong-yuan Z: Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer. Laryngoscope; 2005 Sep;115(9):1574-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features, treatment, and prognosis of postirradiation osteosarcoma in patients with nasopharyngeal cancer.
  • OBJECTIVES: Postirradiation osteosarcoma (PIOS) arising after radiation of nasopharyngeal cancer (NPC) is rare and seldom reported.
  • Their clinical records, image and pathologic slides, and follow-up data after treatment were collected to perform analysis.
  • The latent time of PIOS after irradiation for NPC ranged from 4 to 27 years, with a mean of 13.3 years.
  • The location where PIOS arose included 33.3% (5/15) from maxilla, 46.7% (7/15) from mandible, and 20% (3/15) from a mixture of nasal cavity and paranasal sinuses.
  • Radiologically, soft tissue mass, bone destruction, and tumor new bone formation were the main characteristics.
  • Pathologic subtypes included 53.3% (8/15) of fibroblastic osteosarcoma, 33.3% (5/15) of chondroblastic osteosarcoma, and 13.3% (2/15) of mixed type osteosarcoma.
  • The survival time after treatment for all patients ranged from 7 to 41 months, with a mean of 18 months.
  • Surgery combined with pre- and postoperative chemotherapy might be an effective way to improve survival.
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Mandibular Neoplasms / pathology. Maxillary Neoplasms / pathology. Middle Aged. Nasal Cavity. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148697.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, Yoon JH: Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol; 2005 Feb;125(2):201-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulindac sulfide-induced apoptosis in sinonasal cancer cells.
  • CONCLUSIONS: These results demonstrate that sulindac sulfide can induce cell death in maxillary cancer cells, and that sulindac sulfide-induced apoptosis is related to the extracellular signal-regulated kinase/p38 MAPK-caspase 3 signaling pathway.
  • OBJECTIVE: Head and neck cancer is the sixth commonest cancer in the human body.
  • Squamous cell carcinoma accounts for most sinonasal cancers.
  • However, little is known regarding the biochemical mechanism(s) of cell death in sinonasal cancers.
  • Recently, human epidemiological and clinical intervention studies have indicated that sulindac, a non-steroidal anti-inflammatory drug, exhibits chemopreventive activity in colorectal cancer.
  • In this study, we aimed to investigate whether sulindac sulfide can induce apoptosis in sinonasal cancer cells and what type of molecular mechanisms induces the death of sinonasal cancer cells.
  • MATERIAL AND METHODS: Sinonasal cancer cells (Asan Medical Center Head and Neck Cancer 5) were treated with various concentrations of sulindac sulfide.
  • RESULTS: Human nasal cavity cancer cells treated with sulindac sulfide underwent cell death, and the induction of apoptosis occurred in a dose-dependent manner.
  • Moreover, sulindac sulfide-induced apoptosis was abolished by treatment with the caspase inhibitor Z-VAD-fmk and the mitogen-activated protein kinase (MAPK) inhibitors PD98059 and SB203580.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Apoptosis / drug effects. Carcinoma, Squamous Cell / drug therapy. Paranasal Sinus Neoplasms / drug therapy. Sulindac / analogs & derivatives. Sulindac / pharmacology. Sulindac / therapeutic use
  • [MeSH-minor] Amino Acid Chloromethyl Ketones / administration & dosage. Amino Acid Chloromethyl Ketones / pharmacology. Caspase Inhibitors. Flavonoids / administration & dosage. Flavonoids / pharmacology. Fluorescence. Humans. Imidazoles / administration & dosage. Imidazoles / pharmacology. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Pyridines / administration & dosage. Pyridines / pharmacology. Signal Transduction / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880954.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Amino Acid Chloromethyl Ketones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Caspase Inhibitors; 0 / Flavonoids; 0 / Imidazoles; 0 / Pyridines; 0 / SB 203580; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 184SNS8VUH / Sulindac; 6UVA8S2DEY / sulindac sulfide; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


25. Guntinas-Lichius O, Kreppel MP, Stuetzer H, Semrau R, Eckel HE, Mueller RP: Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients. Eur J Surg Oncol; 2007 Mar;33(2):222-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single modality and multimodality treatment of nasal and paranasal sinuses cancer: a single institution experience of 229 patients.
  • AIMS: To assess the single and multimodal treatment results and prognostic factors for sinonasal carcinoma.
  • METHODS: Overall survival (OS), disease-specific survival (DSS), local control (LC), and disease-free survival (DFS) in 229 patients with sinonasal carcinoma treated from 1967 to 2003 were calculated.
  • RESULTS: 32% of the patients were operated only, 47% underwent multimodal therapy, and 20% were treated without operation.
  • Prognostic for DSS were M status (p<0.001), UICC stage (p<0.001), T classification (p=0.001), N status (p=0.002), intracranial tumor infiltration (p=0.008), infiltration of the pterygopalatine fossa (p=0.02), infiltration of the skull base (p=0.021), infiltration of the orbita (p=0.041), and the type of therapy (p<0.001): The 5-year DSS rate was 63% for patients operated only, 56% for all operated patients, 46% for patients undergoing surgery and radiotherapy, but only 21% for patients treated with radiotherapy+/-chemotherapy.
  • Multivariate analysis revealed that T classification (p=0.042), N classification (p=0.035), M classification (p=0.007), UICC stage (p=0.038), and type of therapy (p=0.038) were independent prognostic factors for DSS.
  • CONCLUSIONS: Radical surgery is recommended for stage I/II sinonasal carcinomas.
  • Stage III/IV carcinomas still have a poor prognosis, but multimodal treatment seems to favor the outcome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Nose Neoplasms / therapy. Otorhinolaryngologic Surgical Procedures / methods. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Germany / epidemiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate / trends. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127030.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M: A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. Laryngoscope; 2000 Oct;110(10 Pt 1):1617-22
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma.
  • OBJECTIVE: Sinonasal undifferentiated carcinoma (SNUC) and sinonasal neuroendocrine carcinoma (SNEC) are relatively newly recognized, rare entities requiring further clinicopathological analysis to advance our understanding and determine prognostic distinctions between them.
  • Histological and immunohistochemical findings, patient demographics, treatment regimens, and outcomes were analyzed and compared.
  • The predominant site was the superior nasal cavity or ethmoids (seven cases), followed by the maxilla (four cases).
  • Of the nine patients who were treated initially with surgical resection, seven received postoperative radiation therapy alone, one received postoperative radiation and chemotherapy, and one had only limited postoperative chemotherapy.
  • One patient was treated with radiation therapy and chemotherapy alone, without surgical resection.
  • CONCLUSIONS: SNUC and SNEC are both aggressive tumors, usually presenting in middle age as a nasal mass.
  • [MeSH-major] Carcinoma / pathology. Nose Neoplasms / pathology. Paranasal Sinuses
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11037813.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Cohen ZR, Marmor E, Fuller GN, DeMonte F: Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus; 2002 May 15;12(5):e3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Olfactory neuroblastoma (ON) is a rare neoplasm arising from the olfactory epithelium and found in the upper nasal cavity.
  • The authors studied the frequency with which ON is misdiagnosed with other tumors of the paranasal sinuses such as neuroendocrine carcinoma (NEC), pituitary adenoma, melanoma, lymphoma, and sinonasal undifferentiated carcinoma (SNUC).
  • Based on the belief that misdiagnosis commonly occurs, they emphasized the importance of establishing the correct diagnosis, because the treatment regimens and prognosis of these tumor types are often significantly different.
  • Anderson Cancer Center between January 1998 and March 2000.
  • Demographic data were collected, physical findings and mode of treatments were documented, and neuroimaging studies were assessed.
  • Eight of 10 patients in whom lesions were misdiagnosed required significant alteration in the initially proposed treatment plan.
  • CONCLUSIONS: Neurosurgeons should be acutely aware of the variety of neoplasms that occur in the paranasal region.
  • The correct diagnosis should be ensured before initiating treatment to provide the optimum therapy and spare the patients from needless and potentially toxic treatment.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Diagnostic Errors. Esthesioneuroblastoma, Olfactory / diagnosis. Melanoma / diagnosis. Nasal Cavity. Nose Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blindness / etiology. Case Management. Cisplatin / administration & dosage. Cisplatin / adverse effects. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Ethmoid Sinus / pathology. Humans. Hypopituitarism / etiology. Iatrogenic Disease. Male. Middle Aged. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Radiation Injuries / etiology. Radiotherapy / adverse effects. Retrospective Studies. Sphenoid Sinus / pathology. Vincristine / administration & dosage. Vincristine / adverse effects


28. Hatoum GF, Patton B, Takita C, Abdel-Wahab M, LaFave K, Weed D, Reis IM: Small cell carcinoma of the head and neck: the university of Miami experience. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):477-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the head and neck: the university of Miami experience.
  • PURPOSE: To describe the University of Miami experience in the treatment of small cell carcinoma of the head and neck.
  • METHODS AND MATERIALS: A total of 12 patients with nonmetastatic small cell carcinoma of the head and neck were treated between April 1987 and September 2007.
  • Radiotherapy was the primary local treatment modality for 8 patients.
  • The Kaplan-Meier estimate of the proportion of small cell head-and-neck cancer patients surviving to 1 and 2 years was 63% and 26%, respectively.
  • The patients with tonsil/parotid gland cancer had significantly greater disease-specific survival compared with the other patients.
  • The median survival time was 30 months in the tonsil/parotid group compared with 15.2 months in the other group (patients with small cell carcinoma of the sinonasal cavity, nasopharynx, and larynx).
  • A total of 4 patients developed recurrence, 3 of whom had a distant failure component.
  • The treatment modality was not associated with a difference in disease-specific survival.
  • The 1-year disease-specific survival rate was 73% in the radiotherapy or radiotherapy/chemotherapy group compared with 67% in the other group.
  • CONCLUSION: Radiotherapy with or without chemotherapy is a reasonable alternative to surgery for patients with small cell carcinoma of the head and neck.
  • More aggressive treatment might be warranted for patients with sinonasal carcinoma.
  • The outcome, however, continues to be suboptimal, and more effective therapy is needed because most patients had a component of local and distant failure.
  • [MeSH-major] Carcinoma, Small Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Florida. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / radiotherapy. Male. Middle Aged. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / mortality. Nasopharyngeal Neoplasms / radiotherapy. Nose Neoplasms / drug therapy. Nose Neoplasms / mortality. Nose Neoplasms / radiotherapy. Parotid Neoplasms / drug therapy. Parotid Neoplasms / mortality. Parotid Neoplasms / radiotherapy. Retrospective Studies. Tonsillar Neoplasms / drug therapy. Tonsillar Neoplasms / mortality. Tonsillar Neoplasms / radiotherapy. Universities

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004574.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM: Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):49-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation.
  • PURPOSE: To review the University of California-San Francisco (UCSF) experience of using intensity-modulated radiation therapy (IMRT) to treat head-and-neck cancer focusing on the importance of target volume delineation and adequate target volume coverage.
  • METHODS AND MATERIALS: Between April 1995 and January 2002, 150 histologically confirmed patients underwent IMRT for their head-and-neck cancer at our institution.
  • Sites included were nasopharynx 86, oropharynx 22, paranasal sinus 22, thyroid 6, oral tongue 3, nasal cavity 2, salivary 2, larynx 2, hypopharynx 1, lacrimal gland 1, skin 1, temporal bone 1, and trachea 1.
  • One hundred seven patients were treated definitively with IMRT +/- concurrent platinum chemotherapy (92/107), whereas 43 patients underwent gross surgical resection followed by postoperative IMRT +/- concurrent platinum chemotherapy (15/43).
  • The average prescription doses to the GTV were 70 Gy and 66 Gy for the primary and the postoperative cases, respectively.
  • The site of recurrence was determined by the diagnostic neuroradiologist to be either within the GTV or the CTV volume by comparison of the treatment planning computed tomography with posttreatment imaging studies.
  • RESULTS: For the primary definitive cases with a median follow-up of 25 months (range 6 to 78 months), 4 patients failed in the GTV.
  • For the primary group, the average maximum, mean, and minimum doses delivered were 80 Gy, 74 Gy, 56 Gy to the GTV, and 80 Gy, 69 Gy, 33 Gy to the CTV.
  • For the postoperative group, the average maximum, mean, and minimum doses delivered were 79 Gy, 71 Gy, 37 Gy to the GTV and 79 Gy, 66 Gy, 21 Gy to the CTV.
  • CONCLUSION: Accurate target volume delineation in IMRT treatment for head-and-neck cancer is essential.
  • Higher treatment failure rates were noted in the postoperative setting in which lower doses were prescribed.
  • [MeSH-minor] Academic Medical Centers. Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiotherapy, Conformal / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1639; author reply 1639-40 [15050350.001]
  • (PMID = 12909215.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Blanch JL, Ruiz AM, Alos L, Traserra-Coderch J, Bernal-Sprekelsen M: Treatment of 125 sinonasal tumors: prognostic factors, outcome, and follow-up. Otolaryngol Head Neck Surg; 2004 Dec;131(6):973-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of 125 sinonasal tumors: prognostic factors, outcome, and follow-up.
  • We reviewed our experience with sinonasal cancer patients to assess the prognostic factors.
  • Surgery as a primary treatment was selected for 106 patients (55 cases of surgery alone, 40 cases of surgery plus radiotherapy, and 11 cases of surgery plus chemotherapy with/without radiotherapy).
  • Histological type and primary site had no prognostic value.
  • Sinonasal tumors have a poor survival, despite early diagnosis, radical surgical resection, and strict follow-up.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577800.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Chen AM, Daly ME, El-Sayed I, Garcia J, Lee NY, Bucci MK, Kaplan MJ: Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck.
  • PURPOSE: To report the clinical outcome of patients treated with combined-modality approaches for sinonasal undifferentiated carcinoma (SNUC) of the head and neck.
  • Primary tumor sites included the nasal cavity (11 patients), maxillary sinus (5 patients), and ethmoid sinus (5 patients).
  • Local-regional treatment included surgery followed by postoperative radiotherapy (PORT) with or without adjuvant chemotherapy for 17 patients; neoadjuvant chemoradiotherapy followed by surgery for 2 patients; and definitive chemoradiotherapy for 2 patients.
  • There was no difference in local control according to initial treatment approach, but among the 19 patients who underwent surgery the 5-year local control rate was 74% for those with gross tumor resection, compared with 24% for those with subtotal tumor resection (p = 0.001).
  • CONCLUSION: The suboptimal outcomes suggest a need for more effective therapies.
  • Gross total resection should be the goal of all treatments whenever possible.
  • [MeSH-major] Carcinoma / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / therapy. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant / methods. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207030.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Rischin D, Porceddu S, Peters L, Martin J, Corry J, Weih L: Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. Head Neck; 2004 May;26(5):435-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma.
  • BACKGROUND: Sinonasal undifferentiated carcinoma (SNUC) is an uncommon malignancy associated with poor prognosis.
  • The optimal treatment approach for SNUC has not been established was performed.
  • METHODS: A retrospective review of all patients with SNUC seen at the Peter MacCallum Cancer Centre over a 12-year period.
  • One patient with a T1N0 nasal cavity tumor treated with radiation alone has not relapsed.
  • CONCLUSION: Induction chemotherapy followed by concurrent chemoradiation is promising treatment strategy for SNUC.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc. Head Neck 26: 435-441, 2004.
  • (PMID = 15122660.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Bell DM, Porras G, Tortoledo ME, Luna MA: Primary sinonasal choriocarcinoma. Ann Diagn Pathol; 2009 Apr;13(2):96-100
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sinonasal choriocarcinoma.
  • Primary choriocarcinoma of sinonasal tract has not been previously documented.
  • The aim of the study was to report, for the first time, 2 cases of primary sinonasal choriocarcinoma.
  • Two male patients of 44 and 49 years of age complained of epistaxis and nasal obstruction of 2-week duration.
  • Computerized axial tomographic scan of the head revealed an opacity of the left nasal cavity in one patient and a destructive lesion of the maxillary sinus in the other.
  • One patient treated with maxillectomy, postoperative radiotherapy, and 5 courses of VIP chemotherapy (cisplatinum, etoposide, ifosfomide) died with brain metastases 10 months after diagnosis.
  • The present cases demonstrated the widespread distribution of germ cell tumors in the human body and lead to further support of the existence of primary choriocarcinomas in the sinonasal tract.
  • Correct identification of this neoplasm is therefore important for institution of specific therapy.
  • [MeSH-major] Choriocarcinoma, Non-gestational / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma / pathology. Chorionic Gonadotropin / blood. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302957.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


34. Chang CW, Wang TE, Chen LT, Chang WH, Leu YS, Fan YK, Chan YJ: Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature. Med Oncol; 2008;25(3):264-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature.
  • Hepatocellular carcinoma with sinonasal metastasis is extremely rare.
  • We report a case of a 49-year-old man who had a history of synchronous hepatocellular carcinoma and verrucous carcinoma of tongue.
  • A painless and non-bleeding mass was found in the left nasal septum 16 months after hepatocellular carcinoma was diagnosed.
  • On computed tomography, the mass was enhanced with contrast.
  • It was resected and proved to be metastatic hepatocellular carcinoma.
  • The patient was treated with radiotherapy to the nasal area and then with chemotherapy.
  • He was still alive, 15 months after the appearance of the nasal metastasis.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Nasal Septum. Nose Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Carcinoma, Verrucous / surgery. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Sep 1;60(5):1107-10 [3038298.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7391-400 [16437707.001]
  • [Cites] Arch Otolaryngol. 1984 Jul;110(7):437-40 [6732584.001]
  • [Cites] Hepatol Res. 2005 Jul;32(3):163-72 [16024288.001]
  • [Cites] Laryngoscope. 1963 Jul;73:942-53 [14043146.001]
  • [Cites] World J Gastroenterol. 2004 Mar 1;10(5):649-53 [14991931.001]
  • [Cites] Cutis. 2000 Feb;65(2):107-9 [10696564.001]
  • [Cites] Arch Otolaryngol. 1984 Sep;110(9):624-7 [6089722.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):369-74 [7686441.001]
  • [Cites] J Formos Med Assoc. 2002 Oct;101(10):715-8 [12517047.001]
  • [Cites] Head Neck Surg. 1982 Sep-Oct;5(1):29-38 [6757187.001]
  • [Cites] Laryngoscope. 1966 Apr;76(4):621-50 [5930356.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2174-9 [2171748.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):796-802 [15305412.001]
  • [Cites] J Laryngol Otol. 1994 Jun;108(6):503-4 [8027653.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1547-50 [15162522.001]
  • [Cites] Indian J Gastroenterol. 1998 Jul-Sep;17 (3):111-2 [9695400.001]
  • [Cites] Korean J Hepatol. 2004 Sep;10(3):228-32 [15385718.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):863-77 [6295617.001]
  • [Cites] HNO. 1991 Jul;39(7):263-5 [1657838.001]
  • [Cites] J Laryngol Otol. 1993 Dec;107(12):1171-3 [8289013.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Apr;263(4):305-7 [16177918.001]
  • [Cites] J Clin Gastroenterol. 1991 Apr;13(2):217-9 [1851774.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jun;122(6):932-3 [10828817.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1907-17 [14667750.001]
  • [Cites] Dig Surg. 2001;18(4):294-7 [11528139.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1343-53 [7882285.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Nov;20(11):1781-7 [16246200.001]
  • [Cites] HNO. 2001 Feb;49(2):126-9 [11270194.001]
  • [Cites] Am J Otolaryngol. 2007 Jul-Aug;28(4):238-41 [17606038.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Mar;55(3):297-306 [9054922.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2005 Aug;102(8):1055-61 [16124714.001]
  • [Cites] Cancer. 1993 May 15;71(10):2941-5 [7683965.001]
  • [Cites] Liver. 2000 Jun;20(3):228-33 [10902973.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Feb;32(1):97-100 [12653243.001]
  • (PMID = 18040899.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins
  • [Number-of-references] 36
  •  go-up   go-down


35. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results.
  • OBJECTIVE: To evaluate the oncologic outcomes of patients with sinonasal cancer treated with endoscopic resection.
  • SETTING: Tertiary care academic cancer center.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Other, less common tumors included adenoid cystic carcinoma (7%), neuroendocrine carcinoma (4%), and sinonasal undifferentiated carcinoma (2%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • CONCLUSIONS: To the best of our knowledge, this is the largest US series to date of patients with malignant tumors of the sinonasal tract treated with endoscopic resection.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Ryuto M, Higaki Y, Tomita K: [Clinical analysis of 16 cases of malignant head and neck melanoma]. Nihon Jibiinkoka Gakkai Kaiho; 2001 Sep;104(9):859-65
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, 1 subjects was amelanotic and 15 melanotic type.
  • Primary lesions were 10 involving the nasal cavity, 2 the paranasal sinus, 2 the gingiva, 1 the lip, and 1 primary unknown.
  • They were treated with or without multimodal surgery, radiation, chemotherapy, and immunotherapy.
  • The prognosis of malignant head and neck melanoma is poor but has gradually improved due to preoperative decisions on disease spread and the introduction of multimodal therapy.
  • [MeSH-major] Head and Neck Neoplasms / therapy. Melanoma / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11605226.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT: Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):410-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
  • PURPOSE: To review the University of Iowa experience with intensity-modulated radiotherapy (IMRT) in the treatment of head-and-neck squamous cell carcinoma.
  • METHODS AND MATERIALS: From October 1999 to April 2004, 151 patients with head-and-neck squamous cell carcinoma were treated with IMRT for curative intent.
  • One patient was lost to follow-up 2 months after treatment and therefore excluded from analysis.
  • Of the remaining 150 patients, 99 were treated with definitive IMRT, and 51 received postoperative IMRT.
  • Sites included were nasopharynx, 5; oropharynx, 56; larynx, 33; oral cavity, 29; hypopharynx, 8; nasal cavity/paranasal sinus, 8; and unknown primary, 11.
  • None of the patients treated with postoperative IMRT received chemotherapy.
  • Of 99 patients who had definitive IMRT, 68 patients received concurrent cisplatin-based chemotherapy.
  • One patient received induction cisplatin-based chemotherapy, but no concurrent chemotherapy was given.
  • The prescribed doses to CTV1, CTV2, and CTV3 in the definitive cohort were 70-74 Gy, 60 Gy, and 54 Gy, respectively.
  • For high-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 64-66 Gy, 60 Gy, and 54 Gy, respectively.
  • For intermediate-risk postoperative IMRT, the prescribed doses to CTV1, CTV2, and CTV3 were 60 Gy, 60 Gy, and 54 Gy.
  • The median time from treatment completion to local-regional recurrence was 4.7 months (range, 1.8 to 15.6 months).
  • Only one marginal failure was noted in a patient who had extensive tonsil cancer with tumor extension into the orbit and cavernous sinus.
  • Patients with oropharyngeal cancer did significantly better than patients with oral cavity and laryngeal cancer, with a 2-year local-regional control rate of 98%, compared with 78% for oral cavity cancer and 85% for laryngeal cancer (p = 0.005).
  • There was no significant difference in local-regional control for patients who received postoperative radiation or definitive radiation (p = 0.339) and for patients who had chemotherapy or not (p = 0.402).
  • CONCLUSIONS: Our results have confirmed the effectiveness of IMRT in head-and-neck cancer.
  • More studies are necessary to further improve the outcomes of laryngeal cancer as well as oral cavity cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Iowa. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Failure. Universities

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168834.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Esposito F, Kelly DF, Vinters HV, DeSalles AA, Sercarz J, Gorgulhos AA: Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies. J Neurooncol; 2006 Feb;76(3):299-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.
  • BACKGROUND: Primary neoplasms of the sphenoid sinus are a rare occurrence, accounting for approximately 1-2% of all paranasal sinus tumors.
  • METHODS: Four patients with sphenoid sinus neoplasms were identified (1%), all treated during the year 2003.
  • MRIs in all patients demonstrated large sphenoid sinus masses with partial clival and sellar bone erosion but with clear visualization of the pituitary gland above the mass.
  • Cavernous sinus invasion was present in all four cases, including one patient with tumor in the ethmoid sinus and intra-tumoral hemorrhage.
  • Tumor histology included neuroendocrine carcinoma, sinonasal undifferentiated carcinoma, mucoepidermoid carcinoma, and giant cell tumor.
  • Metastatic work-ups were negative in all patients, and all received fractionated stereotactic radiotherapy; three received chemotherapy.
  • In this small series, they presented with cavernous sinus symptoms and headache but not endocrinopathy.
  • Their aggressive nature warrants a multimodality treatment plan including surgical debulking, radiotherapy, and chemotherapy in some cases.
  • [MeSH-major] Neurosurgical Procedures. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Giant Cell / metabolism. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / therapy. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):761-76 [6319335.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Laryngoscope. 1989 Jul;99(7 Pt 1):716-20 [2747395.001]
  • [Cites] Laryngoscope. 1963 May;73:537-46 [14011951.001]
  • [Cites] Cephalalgia. 1988 Dec;8(4):229-36 [3219724.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Yonsei Med J. 1988;29(3):209-18 [3057747.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):160-5; discussion 166 [8647682.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):602-8; discussion 608-9 [8232799.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1973 Aug;83(8):1252-65 [4758128.001]
  • [Cites] Pituitary. 2002;5(4):261-5 [14558675.001]
  • [Cites] World J Surg. 2003 Jul;27(7):849-55 [14509518.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Jun;41(2):66-73 [9651913.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):663-72 [12152781.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):581-9 [1503031.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol. 1978 Oct;104(10):585-7 [697636.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):709-16 [2115658.001]
  • [Cites] Eur J Pediatr. 1996 Aug;155(8):717-9 [8839732.001]
  • [Cites] J Otolaryngol. 1990 Apr;19(2):122-9 [2348505.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):208-12 [2037472.001]
  • [Cites] Med J Aust. 2000 Nov 20;173(10):548-9 [11194741.001]
  • [Cites] Neuroradiology. 1998 Oct;40(10 ):651-5 [9833894.001]
  • [Cites] Brain. 1984 Sep;107 ( Pt 3):855-70 [6478180.001]
  • [Cites] J Craniofac Surg. 1995 Jan;6(1):15-23 [8601000.001]
  • [Cites] J Neurosurg Sci. 1999 Mar;43(1):25-36 [10494663.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Br J Neurosurg. 1994;8(1):51-5 [8011194.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 May;259(5):266-8 [12107531.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Pathology (Phila). 1996;3(2):513-34 [8795833.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jan;120(1):19-25 [8274251.001]
  • [Cites] Am J Emerg Med. 2001 Jan;19(1):88-90 [11146033.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1126-35; discussion 1135-7 [14580279.001]
  • [Cites] Cancer. 1977 Dec;40(6):3038-41 [412586.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):951-5 [7499947.001]
  • (PMID = 16163447.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Babin E, Rouleau V, Vedrine PO, Toussaint B, de Raucourt D, Malard O, Cosmidis A, Makaeieff M, Dehesdin D: Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. J Laryngol Otol; 2006 Apr;120(4):289-97
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses.
  • INTRODUCTION: Small cell neuroendocrine carcinoma (SNEC) of the sinonasal tract is a rare disease.
  • OBJECTIVE: Report a descriptive study of a relatively large cohort of SNEC of the nasal cavity and paranasal sinuses.
  • METHOD: The medical records of 21 patients presenting with nasal and paranasal SNEC to various French hospitals, from 1989 to 2003, were analysed to determine the clinical features and current treatment of the disease.
  • Patients' staging for nasal cavity malignancy was: T1, four; T2, three; T3, one; T4, 13; N0, 18; N2, three; M0, 20; and M1, one.
  • None of the patients suffered from SNEC of the sinonasal tract with ectopic hormone production.
  • One patient had an adenocarcinoma and an inverted papilloma associated with neuroendocrine carcinoma.
  • Patients underwent surgery (11 cases), radiotherapy (14 cases) and chemotherapy (12 cases).
  • CONCLUSION: Small cell neuroendocrine carcinoma of the sinonasal tract is an uncommon neoplasm with aggressive clinical behaviour.
  • However, the current treatment of these neuroendocrine neoplasms varies widely.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526967.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


40. Kumar M, Bahl A, Sharma DN, Sharma R, Gupta R, Ahmed S, Julka PK, Rath GK: Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma. J Cancer Res Ther; 2009 Apr-Jun;5(2):124-6
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cylindric cell carcinoma of the base of the tongue: a rare variant of squamous cell carcinoma.
  • They have been known by myriads of nomenclature like cylindric carcinomas, nonkeratinizing sinonasal carcinoma, papillary carcinoma, cylindrical or columnar cell carcinoma, intermediate cell carcinoma, Schneiderian carcinoma, and Ringertz carcinoma.
  • They are considered a variant of nonkeratinizing squamous cell carcinoma.
  • Cylindric carcinomas are usually described in the sinus and nasal cavity and rarely said to involve nasopharynx and larynx.
  • We report here a rare case of transitional cell carcinoma presenting in the base of the tongue.
  • There are no separate treatment recommendations in the literature, and the management is on the lines of treatment of squamous cell carcinoma.
  • We report here a case of cylindric cell carcinoma presenting in the base of the tongue.
  • The patient received palliative radiotherapy of 20 Gy in five fractions followed by chemotherapy with injection paclitaxel and carboplatin.
  • A partial response to treatment was achieved at the time of writing this report.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542670.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


41. Diba R, Saadati H, Esmaeli B: Outcomes of dacryocystorhinostomy in patients with head and neck tumors. Head Neck; 2005 Jan;27(1):72-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Cancer Center between 1999 and 2003 were retrospectively reviewed.
  • RESULTS: The tumor diagnoses were squamous cell carcinoma (n = 18), chondrosarcoma (n = 3), sinonasal carcinoma (n = 2), adenoid cystic carcinoma (n = 2), sinonasal papilloma (n = 2), esthesioneuroblastoma (n = 1); hemangiopericytoma (n = 1); ameloblastoma (n = 1), and osteosarcoma (n = 1).
  • Twenty-eight patients had a maxillectomy or other sinus surgeries, 10 had radiotherapy, and 14 had chemotherapy and radiotherapy before DCR.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Ethmoid Bone / surgery. Female. Humans. Male. Maxilla / surgery. Middle Aged. Paranasal Sinuses / surgery. Radiotherapy, Adjuvant. Recurrence. Retrospective Studies. Sphenoid Bone / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley Periodicals, Inc.
  • (PMID = 15565560.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Kim JH, Chang JH, Rhee KH, Yoon JH, Kwon SH, Song K, Lee KW, Cho CI, Jeon JH, Kim KS: Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene. Int J Cancer; 2008 Apr 15;122(8):1765-73
Hazardous Substances Data Bank. INDOMETHACIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase inhibitors induce apoptosis in sinonasal cancer cells by increased expression of nonsteroidal anti-inflammatory drug-activated gene.
  • Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) has recently been shown to be induced by nonsteroidal anti-inflammatory drugs (NSAIDs) and to have proapoptotic and antitumorigenic activities.
  • Although sulindac sulfide induced apoptosis in sinonasal cancer cells, the relationship between NAG-1 and NSAIDs has not been determined.
  • In this study, we investigated the induction of apoptosis in sinonasal cancer cells treated by various NSAIDs and the role of NAG-1 expression in this induction.
  • The effect of NSAIDs on normal human nasal epithelial (NHNE) cells was also examined to evaluate their safety on normal cells.
  • In AMC-HN5 human sinonasal carcinoma cells, indomethacin was the most potent NAG-1 inducer and caused NAG-1 expression in a time- and dose-dependent manner.
  • Conditioned medium from NAG-1-overexpressing Drosophila cells inhibited proliferation of sinonasal cancer cells and induced apoptosis.
  • In conclusion, indomethacin exerts proapoptotic and antitumorigenic effects in sinonasal cancer cells through the induction of NAG-1 and can be considered a safe and effective chemopreventive agent against sinonasal cancer.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Cyclooxygenase Inhibitors / pharmacology. Cytokines / metabolism. Indomethacin / pharmacology. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Growth Differentiation Factor 15. Humans. Mice. Mice, Nude. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Transfection. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076062.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cyclooxygenase Inhibitors; 0 / Cytokines; 0 / GDF15 protein, human; 0 / Gdf15 protein, mouse; 0 / Growth Differentiation Factor 15; 0 / RNA, Small Interfering; XXE1CET956 / Indomethacin
  •  go-up   go-down






Advertisement